# Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan

> **NCT01004159** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 20 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** cetuximab with irinotecan

## Key facts

- **NCT ID:** NCT01004159
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** former PI left institute
- **Last updated:** 2015-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004159, "Cetuximab Plus Irinotecan in Colorectal Cancer Patients Who Progressed After Failure With Cetuximab Plus Irinotecan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01004159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*